Genetic variants in COMT and ESR1 genes shape treatment response to raloxifene in schizophrenia-spectrum disorders.
Brand BA. et al, (2025), Psychoneuroendocrinology, 172
Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition.
Brand BA. et al, (2024), Arch Womens Ment Health, 27, 931 - 941
Psychiatrists effect on positive symptom severity and daily functioning during pharmacotherapy for first-episode psychosis patients.
de Beer F. et al, (2024), Sci Rep, 14
Correction to: Evidence‑Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.
Brand BA. et al, (2024), Curr Psychiatry Rep, 26, 550 - 551
Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder.
Brand BA. et al, (2024), Am J Psychiatry, 181, 893 - 900
The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogen.
Hamers IMH. et al, (2024), Schizophr Res, 270, 273 - 280
Sex differences need to be considered when treating women with psychotropic drugs.
Sommer IE. et al, (2024), World Psychiatry, 23, 151 - 152
Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium.
Koops S. et al, (2024), Schizophr Bull, 50, 5 - 8
The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial.
Brand BA. et al, (2023), Schizophr Bull, 49, 1579 - 1590
Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.
Brand BA. et al, (2023), Curr Psychiatry Rep, 25, 723 - 733
Antipsychotic medication for women with schizophrenia spectrum disorders - CORRIGENDUM.
Brand BA. et al, (2023), Psychol Med, 53
Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis.
Oomen PP. et al, (2023), Psychol Med, 53, 2317 - 2327
Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.
Sommer IE. et al, (2023), Schizophr Bull, 49, 136 - 143
[Antipsychotic drugs for women: a narrative review and clinical guidelines].
de Boer JN. et al, (2023), Tijdschr Psychiatr, 65, 87 - 94
Towards better care for women with schizophrenia-spectrum disorders.
Brand BA. et al, (2022), Lancet Psychiatry, 9, 330 - 336
Antipsychotic medication for women with schizophrenia spectrum disorders.
Brand BA. et al, (2022), Psychol Med, 52, 649 - 663
Characterizing speech heterogeneity in schizophrenia-spectrum disorders.
Oomen PP. et al, (2022), J Psychopathol Clin Sci, 131, 172 - 181
Medication strategies in first episode psychosis patients: A survey among psychiatrists.
Kikkert MJ. et al, (2022), Early Interv Psychiatry, 16, 139 - 146
[Improving care for women with schizophrenia-spectrum disorders].
de Boer JN. et al, (2022), Tijdschr Psychiatr, 64, 500 - 503
Estrogens in schizophrenia: progress, current challenges and opportunities.
Brand BA. et al, (2021), Curr Opin Psychiatry, 34, 228 - 237